The TAA-treated groups reported significant differences in survival rate: 48% in the WT-HE group, 46.5% in the Lrrk2G2019S-HE group, but only 25.4% in the Lrrk2−/−-HE group (Fig. 1B) (Pairwise comparison between groups shown in Supplementary Fig. 1), indicating that LRRK2 deficiency significantly increases the mortality of mice after TAA intervention. This evidence concerns the gene LRRK2 and hereditary elliptocytosis.